|
Post by aqt on Nov 20, 2009 7:48:20 GMT -5
www.darpa.mil/dso/archives/bioflips/index.htmThe BioFlips Program demonstrated technologies for integrated biofluidic microprocessors capable of on-chip reconfiguration and self-calibration via feedback control. The prototypes developed in the program included on-chip sample-to-answer biological fluid assays for real-time monitoring of a soldier's health parameters. For DoD applications, complete "sample-to-answer" solutions in chip-scale devices are needed for robust, easy-to-use packages with minimum payload.The BioFlips projects included four categories of deliverables: (1) front-end sample processing, (2) integrated detection architectures, (3) novel fluidic transport, and (4) integrated chip-scale applications. Projects developed platforms to tackle critical technical barriers of total integration. These platforms provided the chip designer the capability to lay out designs for integrated systems by simply connecting the components with predictable performance specifications. Compatible microfabrication technologies were developed to integrate multiple fluidic components (structures, sensors, and actuators), different materials, and different processes onto chip-scale devices. The program integrated on-chip fluidic transport components with sensors for dynamically controlled surface properties that enabled active chips by feedback control. These active chips are capable of reconfiguration and self-calibration.thanks SS and LM!!!!!!!!! aqt
|
|
|
Post by aqt on Nov 20, 2009 9:18:18 GMT -5
Patterning of Embryonic Stem Cells Using the Bio Flip Chip www.jove.com/index/details.stp?ID=318sky, morphogens pattern embryonic stem cells BioFlip chip as a morphogen? bet they used embryonic stem cells in the creation of this as well as insect and plant stem cells stem cells are a "blank slate" until a certain chemical reaction takes place and tells the cell what type of cell to become, whether from a human embryo, a plant or an insect. aqt
|
|
|
Post by aqt on Nov 20, 2009 9:20:43 GMT -5
|
|
|
Post by aqt on Nov 20, 2009 9:23:31 GMT -5
en.wikipedia.org/wiki/Flip_chipFlip chip, also known as Controlled Collapse Chip Connection or its acronym, C4, is a method for interconnecting semiconductor devices, such as IC chips and MEMS, to external circuitry with solder bumps that have been deposited onto the chip pads. The solder bumps are deposited on the chip pads on the top side of the wafer during the final wafer processing step. In order to mount the chip to external circuitry (e.g., a circuit board or another chip or wafer), it is flipped over so that its top side faces down, and aligned so that its pads align with matching pads on the external circuit, and then the solder is flowed to complete the interconnect. This is in contrast to wire bonding, in which the chip is mounted upright and wires are used to interconnect the chip pads to external circuitry
|
|
|
Post by aqt on Nov 20, 2009 9:26:35 GMT -5
DR FLIP CHIP? www.drflipchip.com/creden.htmlFLIP CHIP Fifteen years in flip chip research, development, manufacturing, training, consulting. Principal investigator for three DARPA flip chip production contracts. Author of 54 flip chip papers and articles, created and maintain FlipChips.com, the leading flip chip education and information site. meaning they have already been put in production three times. aqt
|
|
|
Post by aqt on Nov 20, 2009 9:31:29 GMT -5
|
|
|
Post by aqt on Nov 20, 2009 9:54:29 GMT -5
|
|
|
Post by aqt on Nov 20, 2009 9:55:30 GMT -5
www.stanford.edu/group/dabmgroup/publications/c26.pdfflip chip bonding to silicone Abstract – We present a post-integration cavity resonance tuning technique for asymmetric Fabry-Perot MQW modulators flip-chip bonded to silicon CMOS. The process relies on highly selective chemical etching and GaAs surface oxidation. High-quality devices are successfully integrated.aqt
|
|
|
Post by aqt on Nov 20, 2009 9:57:50 GMT -5
|
|
|
Post by aqt on Nov 20, 2009 9:59:56 GMT -5
|
|
|
Post by aqt on Nov 20, 2009 10:08:43 GMT -5
|
|
|
Post by aqt on Nov 20, 2009 10:11:12 GMT -5
|
|
|
Post by aqt on Nov 20, 2009 10:16:31 GMT -5
|
|
|
Post by sam on Nov 20, 2009 10:57:17 GMT -5
Blank State Technology -------------------------------------------------------- 146.186.172.254/crossover2005/NicholsAbstract.htmlStem Cell Bioengineering; EMF, and Glycosylation cell signaling Trent Nichols MD. StemNetics and AMRI PA. Clinical Associate Professor Penn State University Medical Center ABSTRACT: It is well-accepted that human stem cells, "blank slate" cells that can become any type of cell in the body, will revolutionize healthcare in a way similar to the introduction of antibiotics during the last century. A rapidly growing body of research supports the promise of stem cells not only in effectively treating, but actually curing, many debilitating or fatal degenerative diseases, as well as spinal cord injuries, stroke, burns and heart disease. Initial research in this area used embryonic stem cells (ES). However, research and use of ES for tissue repair has been severely restricted worldwide due to ethical considerations in destroying human embryos to obtain these cells. Current ES cell lines that differentiate well do not proliferate well, which also limits their therapeutic use as well as the contamination with mouse feeder cells. Fortunately, recent research has discovered that most adult tissues retain a small population of adult stem cells (AS) which in many cases appear to be as flexible as ES in becoming any type of specialized cell. Importantly, AS taken from an individual retain the immunological identity of that individual, so tissues made from these adult cells will not be immunologically rejected when reintroduced into the body. Unfortunately, there are only a few AS in each type of body tissue, and until now no reliable, effective way has been found to rapidly grow these cells outside of the body while maintaining their ability to become the desired type of specialized cell. StemNetics is a startup bioengineering company developing novel technologies for repair of damaged tissues and organs in patients without the need for artificial transplants or toxic immunosuppressant drugs. The Company is a spin-off of the Advanced Magnetic Research Institute which is exploring use of DC high magnetic fields, undergoing phase III trials for the FDA approval for use in patients as an experimental therapy for degenerative diseases, to stimulate controlled growth and specialization of adult stem cells. StemNetics expects to solve this roadblock to using AS as "the perfect medicine" through novel proprietary and exclusively licensed technologies. The Company is investigating pulsed and high field energy electromagnetics and novel biochemical approaches to stimulate the growth and specialization of adult stem cells in the lab needed to make healthy tissue for transplantation back into the body. Preliminary clinical and laboratory studies support the Company's approach. When fully developed, StemNetic's technologies are expected allow cost-effective AS commercialization for research and therapeutics. Research with pulsed low maqnetic field has already demonstrated that exposure to ELF can act as a differenting agent on mesenchymal human cells in vitro and outlines the importance of low frequency electro-magnetic field as a therapeutically agent. Target Markets Stem cells have potential applications in at least two multi-billion-dollar markets: biomedical research (basic research, drug discovery, diagnostics development) and therapeutics (bioengineered tissues; gene delivery; cell therapy). •Biomedical research. This is a $3 billion market for research biologicals, with an annual growth rate of 10-15%. Stem cells could eventually represent $150-200 million per year in this market. •Diagnostics & Therapeutics. This is a greater than $30 billion market. Stem cells are quite different from most existing therapeutics, as they represent a potential cure rather than just a treatment. • Completive Advantage.StemNetics has an exclusiveworldwide license to use a unique high energy magnetics technology, Magnetic Molecular Energetics or MME (US patent.6, 210,317) now undergoing approval by the FDA for whole-body treatment of degenerative diseases, as a method to stimulate growth of AS in the lab for direct injection into target organs. The Company has ongoing access to the needed equipment and facilities at the Advanced Magnetic Research Institute (AMRI) through one of the Company’s co-founders, Dr. Trent Nichols. The other co-founder of StemNetics is Dr. Kevin J. Yarema at Johns Hopkins University. Dr. Yarema is developing novel biochemical (glycosylation engineering) techniques for controlled AS specialization that will be licensed exclusively to the Company. StemNetics intends to aggressively protect its intellectual property through patenting (e.g., the cell signaling EMF device) and proprietary exclusivity.
|
|
|
Post by sam on Nov 20, 2009 11:12:18 GMT -5
|
|
|
Post by sam on Nov 20, 2009 11:13:43 GMT -5
|
|
|
Post by lilsissy on Nov 24, 2009 14:12:24 GMT -5
I am freakin out right now, listen to this one. I hit your link aqt about flipchip and read for about one minute, decided to get back to it later. I googled ionic layers flipped atmosphere up comes the flip chip, boooooo scary, jen
|
|